



Vivimed

Investor Release

**Clarification in relation to news Article on “Vivimed Life Sciences Pvt Ltd(Vivimed) recalls hypertensive drug from US market due to impurities - Losartan Potassium is indicated for the treatment of hypertension, hypertensive patients with left ventricular hypertrophy, nephropathy in Type 2 diabetic patients “**

**Hyderabad, India, May 8, 2019 – Vivimed Labs Ltd (VLL) clarifying that ,the above news is relating to Vivimed Life Sciences Pvt Ltd (erstwhile subsidiary of Vivimed Labs Limited) .**

Vivimed Labs Limited vide its press release dated January 29,2019 informed the public about its Board decision to Sell its stake in 50:50 JV with Strides for augmenting management focus on the growing FDF portfolio across India, RoW and CIS markets and also to Improve financial flexibility for the domestic finished dosage business and reduction of long term leverage in the Indian operations. Consequently, VLL Sold balance 50% stake in Vivimed Life Sciences Private Limited, India to Strides Pharma Science Limited and the balance 50% stake in Strides Vivimed Pte Ltd, Singapore to Strides Pharma Global Pte, Singapore .

Hence the above news has no effect on business of Vivimed Labs Limited.

For further information on Vivimed, visit [www.vivimedlabs.com](http://www.vivimedlabs.com)

\*\*\* \*\*

#### Safe Harbour

This release contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed’s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For VIVIMED LABS LTD.

**K. YUGANDHAR**  
Company Secretary  
ACS No. 19315



Vivimed

For further information please contact:


**Company Contact:**

Vivimed Labs Limited  
CIN No: L02411KA1988PLC009465

**Sunil Arab**, VP Corporate Strategy  
Phone: 040-66086608  
Email: [sunil.arab@vivimedlabs.com](mailto:sunil.arab@vivimedlabs.com)

**Investor Relations:**

Citigate Dewe Rogerson Communications Pvt Ltd.  
CIN No: U67190MH1999PTC119332  
Gavin Desa / Suraj Digawalekar  
Phone: +022 6645 1237 / 19  
E-Mail: [gavin@cdr-india.com](mailto:gavin@cdr-india.com)  
E-Mail: [suraj@cdr-india.com](mailto:suraj@cdr-india.com)

For VIVIMED LABS LTD.  
  
K. YUGANDHAR  
Company Secretary  
ACS No. 19315